Plastic Surgery + Endocrine Data Confirm 'Ozempic Face': 9% Midface Volume Loss per 10 kg, 50% Surge in Face-Grafting Demand
DistilINFO and an Endocrine review published May 1 consolidated the clinical literature on accelerated facial aging in patients on GLP-1 receptor agonists. A 2025 Vanderbilt study reported approximately 9% midface volume loss per 10 kg of total weight loss, with GLP-1-mediated lipolysis disproportionately affecting superficial and medial cheek fat pads. The American Academy of Facial Plastic and Reconstructive Surgery reported a 50% increase in face-grafting procedures in the past year tied to the trend, and one in four surgeons expects continued growth in nonsurgical demand (fillers, microneedling, RF, CO2 laser). Mechanistic work in Endocrine adds a possible direct effect on adipose-derived stem cells beyond rapid fat loss alone.